Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO) was the recipient of a large growth in short interest in April. As of April 15th, there was short interest totalling 1,250,000 shares, a growth of 26.5% from the March 31st total of 988,400 shares. Based on an average daily trading volume, of 1,810,000 shares, the days-to-cover ratio is presently 0.7 days. Approximately 3.2% of the shares of the stock are sold short.
Several brokerages have recently issued reports on ARPO. HC Wainwright restated a “hold” rating on shares of Aerpio Pharmaceuticals in a research report on Monday, March 15th. Zacks Investment Research upgraded shares of Aerpio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 price target on the stock in a report on Thursday, March 18th.
Hedge funds have recently modified their holdings of the business. Virtu Financial LLC grew its stake in Aerpio Pharmaceuticals by 363.1% in the 4th quarter. Virtu Financial LLC now owns 171,089 shares of the company’s stock worth $168,000 after acquiring an additional 134,143 shares in the last quarter. Keudell Morrison Wealth Management purchased a new stake in shares of Aerpio Pharmaceuticals in the 1st quarter worth approximately $40,000. Renaissance Technologies LLC lifted its position in shares of Aerpio Pharmaceuticals by 21.1% in the 4th quarter. Renaissance Technologies LLC now owns 1,799,044 shares of the company’s stock worth $1,763,000 after purchasing an additional 313,860 shares during the period. Panagora Asset Management Inc. purchased a new stake in shares of Aerpio Pharmaceuticals in the 4th quarter worth approximately $44,000. Finally, Satter Management CO. L.P. purchased a new stake in shares of Aerpio Pharmaceuticals in the 4th quarter worth approximately $5,509,000. Institutional investors and hedge funds own 34.53% of the company’s stock.
Aerpio Pharmaceuticals (NASDAQ:ARPO) last issued its quarterly earnings results on Wednesday, March 10th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.03. As a group, analysts predict that Aerpio Pharmaceuticals will post -0.14 earnings per share for the current fiscal year.
About Aerpio Pharmaceuticals
Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing compounds that activate Tie2 for the treatment of ocular disease and vascular stabilization. The company's lead product candidate is razuprotafib, a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase , which has completed phase IIb clinical trial for the treatment of non-proliferative diabetic retinopathy, as well as has completed phase II clinical trial for the treatment of patients with open angle glaucoma/ocular hypertension.
Featured Story: What is the return on assets (ROA) ratio?
Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.